Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice

Table 1 Background characteristics of survey respondents

Parameter		n (%)
	University hospital	256 (78.8)
Practice setting	Regional/district hospital	33 (10.1)
	Outpatient clinic	36 (11.1)
	Less than 25%	183 (55.3)
IBD in clinic	25% or more (IBD expert)	148 (46.7)
Years of practice, median (IQR, range)		10.5 (5-20, 0.5-60)
Country of practice	Australia	31 (9.1)
	Brazil	22 (6.5)
	Canada	40 (11.8)
	China	38 (11.2)
	France	9 (2.6)
	Greece	46 (13.5)
	Israel	33 (9.7)
	Italy	19 (5.8)
	South Korea	20 (5.9)
	Serbia	10 (2.9)
	United Kingdom	19 (5.8)
	United States	53 (15.6)

Table 2 Uni-variant and multi-variable analysis of factors for their association with prescribing combination 5-Aminosalycilates + corticosteroids to a hospitalized moderate-severe ulcerative colitis patient

Variable	Rate	Unadjusted odds ratio for prescribing combination 5ASA + CS	95%CI	P value	Adjusted odds ratio for prescribing combination 5ASA + CS	95%CI	P value
Believe 5ASA are very safe	94%	4.20	1.02-17.1	0.045	2.9	0.4-22	0.3
Believe 5ASA are not expensive	53%	1.45	0.88-2.3	0.140	1.3	0.7-2.6	0.4
Believe 5ASA mode-of-action may synergize with CS	60%	7.30	4-13.3	0.001	7.9	3.8-17	< 0.001
IBD expert	55%	0.63	0.39-1.03	0.070	0.6	0.3-1.2	0.14
Work in out-patient clinic setting	11%	3.70	1.3-11.1	0.010	2.7	0.6-12	0.2
Years of practice (odds ratio/yr)	-	-	-	-	0.97	0.94-0.99	0.04

5ASA: 5-Aminosalycilates; CS: Corticosteroids; IBD: Inflammatory bowel disease.